High Dose SBRT for Abdominal-Pelvic Lymph Nodal Lesions in Oligometastatic Patients

Inclusion Criteria: * Age ≥18 years * WHO performance status ≤ 2 * Histologically-proven of primary cancer disease * M1 stage with primary cancer site radically treated with complete response/resection or stable. No other site of disease in progression (a maximum of 3 lymph node sites of disease to treat) * Diameter ≤ 5 cm * Abdomen/pelvic site * Informed consent. Exclusion Criteria: * Patients were required to have not brain metastases or bone metastases. * Patients with a life expectancy of \>3 months. * Any serious disease contraindicated radiation therapy * Other coexisting malignancies, uncontrolled intercurrent illness, active infectious processes, and exudative, bloody, or cytologically malignant effusions excluded patients from the trial. Additionally, patients were excluded from the trial if they were receiving any systemic chemotherapy during radiotherapy, although hormonal therapy was allowed.